Hacked By XwoLfTn

Hacked By XwoLfTn – Tunisian Hacker

EU-MSC2-meeting report

RETHRIM investigates the use of Mesenchymal Stromal Cells (MSC) for the treatment of Graft versus Host Disease. In this affliction which can occur as a side effect of hematopoietic stem cell transplantation the body of the stem cell recipient is attacked by the stem cell graft ou acheter cialis pas cher. The immune system within the patient goes haywire and needs to be controlled. MSC can be used to dampen the immune response especially in patients that do not respond to more conventional immune dampening treatments such as steroids.

The immune suppressive properties of MSC can be used in a number of diseases in which the immune system needs to be controlled more rigorously. Examples are diabetes in which the body attacks it’s own insuline producing cells or Crohn’s disease in which the immune system reacts too strongly affecting the patients intestines.

A number of research groups within the European Union work on MSC, investigating the potential use of these cells to treat a variety of diseases. To learn from each others expertise, exchange ideas and to further research on MSC across Europe these research groups met a while ago. The members of RETHRIM were present at this meeting to share their knowledge on clinical trial using MSC. Interested in the results of that meeting? See the report of the EU-MSC2 meeting below.


RETHRIM project launch

lauch banner

RETHRIM is a research consortium sponsored by the European Union’s Horizon 2020 research and innovation programme. The consortium is coordinated by Prof. WE Fibbe from the Leiden University Medical Centre (LUMC) and started in January 2015 with a budget of 5.9 million Euros over 5 years. The consortium had its kick-off meeting on March 2-3, 2015 in the Leiden Observatory in the Netherlands.

Stem cell regenerative therapies hold great promise for patients suffering from a variety of disorders. Mesenchymal Stromal Cells (MSC) which are currently tested in a large number of clinical trials are promising candidate cells for regenerative therapies. However, their presumed effectiveness is based on small non-controlled phase I/II studies. Results of controlled randomized studies are not available hampering safety and efficacy assessment. The RETHRIM consortium has developed an academic infrastructure for the harmonized production of MSC and assembled clinical experts to conduct the first Europe-wide multi-centre placebo controlled randomized phase III trial using MSC regenerative therapy for the treatment of steroid-resistant visceral GvHD.

Central to the RETHRIM project is the clinical trial for which 150 patients will be recruited. All MSC products will be extensively analysed using molecular and functional markers in order to develop a potency signature for the product whereas patient samples will be used to develop assays for the prediction of clinical response. Alongside the clinical trial, data from quality of life, health technology assessment and ethical studies will be collected. Output from these studies will allow the consortium to formulate a set of measures to convince health authorities, regulatory bodies and insurance companies on the usefulness of MSC therapy and provide suggestions and recommendations for changes in clinical practise, legislation and regulation of MSC regenerative therapy.

For further information: www peut on acheter du cialis sur


  • Coordinator Prof. Dr. Wim Fibbe, Head of the Department of Immunohematology and Blood Transfusion and Director of Division 4, LUMC
  • Project Manager, Dr. Brigitte Wieles, Dept. of Immunohematology and Blood Transfusion, LUMC,

RETHRIM receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643580 and the clinical trial is sponsored by HOVON.



<img class="alignleft wp-image-74 size-full" src=" commander cialis sur internet.jpg” alt=”RETHRIM logo KLEIN” width=”220″ height=”84″ />



Welcome to the RETHRIM website. RETRHIM is an EU financed research consortium interested in Regeneration Through Immunemodulation. The RETHRIM project started on 1-1-2015 and will be active for 5 years.